Amarin Corp PLC (AMRN) Quote

Ohhhhh ralphey u so clever. Heheheheheeee clever fella

DUBLIN, Ireland and BRIDGEWATER, N.J., April 24, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its support for a petition filed with the U.S. Food and Drug Administration (FDA) requesting that the Commissioner focus on and take further action to address significant off-label prescribing of fenofibrates, due to the fact that multiple clinical trials have proven fenofibrates have no clinical benefit when used in combination with statins to reduce cardiovascular disease (CVD) risk. The filing comes as heart disease continues to be the leading cause of death in the United States, accounting for one in five deaths in 2021.1,2 Approximately 805,000 people in the United States have a heart attack each year, which amounts to one person every 40 seconds.1 The annual treatment cost for CVD is $555 billion, which is expected to double within 20 years.3

Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Why am I excited to see an after market share price of 0.95?

I definitely have Stockholm Syndrome.

I think we're in good shape if Judge Andrews family members have loaded up on a sufficient number of AMRN shares by then..............A CYNICAL LONG WOULD SAY

Have to agree with you Laurent. No other way to read the demeanor and thoughts of the 3 judges. Hopefully the trial judge is not pissed but follows their directives.

I think the reversal of dismissal is pretty much a sure shot. (we got the dream team in Moore, Albright, Lourie and they clearly thought dismissal was premature.) The big question is what happens when it lands back on Judge Andrew's docket. We'd have to survive summary judgement before we get to a jury trial.

I'm agree with the UK approval of share buyback and as for the appeal, we can only stick with the positive tones from the 3 judges, however, even at that, it is not a guarantee.
But, we do need both of these to occur quickly to begin some positive movement of the sp.

Maybe Amarin should get hackers to collate the data on V:

https://www.reuters.com/technology/cybersecurity/unitedhealth-says-hack-could-impact-data-substantial-proportion-americans-2024-04-22/

Someone should also file a CP with the FDA to discontinue the use of LOVAZA and all mixed OMG-3 PUUFA's for the same reason as the CP by Womens Health to discontinue fenofibrates. "There is no clinical benefit for its use."

We need to stay on offense and keeping these press releases top of mind.....

https://finance.yahoo.com/news/amarin-applauds-healthywomen-citizen-petition-180000604.html

One of the big sticking points for the German G-BA was their clinical assessment of the outcomes of the REDUCE-IT trial and their interpretation of the "Level of Evidence" regarding "bias" in those outcomes. IMO, they placed far too much scrutiny on the mineral oil placebo as a contradictor of high-quality evidence while ignoring other biasing risk factors.

For example: The Gold Standard for assessing the risk of bias in randomized clinical trails (RCT's), is the "Cochrane Risk of Bias Assessment Tool." This Tool rates 7 bias risk factors as either Low, High or unclear. The 7 bias risk factors are:
Randomization, Allocation concealment, Participants & personnel, Outcome assessment, Selective Outcome reporting, Incomplete outcome data, and Other.

The REDUCE-IT Trial rated a "Low Risk of bias" in each category. The mineral oil hoax would fall under the "Outcome assessment" category. Furthermore, new data is continuing a steady stream of Evidence Based Medicine (#EBM) that IMO, completely debunks the mineral oil conspiracy. Germany, France and Italy need to get their shit together before MACE gets out of control in their countries.

DAR3

Not sure but I would be betting that the UK approval is a done deal after the share holders approval . What would be a reason to say no ?
Also I am not 100% sure that we will win the appeal case. I remember everyone including out side analysts thinking we had a sure win with judge Du

Michael

Some sad history: New Jersey Rep. Donald Payne Jr. dies from a cardiac episode related to complications from diabetes at age 65. He had been hospitalized, unconscious, since early April, per reports in N.J. newspapers.

Cantor was named as being the company that will acquire the shares for Amarin and then move them to Amarin. Not sure if any of the initial purchases have been made prior to the UK approval for Amarin to use on hand capital for those shares.

Well since you have an email relationship with Denner ...ask him why Germany is not onboard .
Kiwi

Kiwi, you are aware that we weren't rejected in Germany because of not enough supportive studies......we were rejected because there was no comparison drug for what our molecule treats so they just picked one that wasn't a good comparative drug to use.

How many times are you going to rehash the same monologue about Germany? I am done reading all of these supposedly explanation why Germany is not on board.

RMB. This is what Germany wants

In Germany, the level of evidence required for the reimbursement of new drugs is quite stringent and follows a systematic process. The German Federal Joint Committee (Gemeinsamer Bundesausschuss or G-BA) is responsible for evaluating the benefits and cost-effectiveness of new drugs to determine whether they should be reimbursed by the statutory health insurance system.

The G-BA typically considers evidence from clinical trials, health economic evaluations, patient-reported outcomes, and real-world data. The level of evidence required includes:

Clinical Trials: High-quality, randomized controlled trials (RCTs) are often required to demonstrate the efficacy and safety of a new drug. These trials should follow rigorous methodologies, including appropriate blinding, randomization, and control groups.
Health Economic Evaluations: Cost-effectiveness analyses are crucial to assess whether the new drug provides value for money compared to existing treatments. This involves comparing the costs of the new drug with its benefits in terms of improved health outcomes.
Patient-Reported Outcomes (PROs): The G-BA also considers patient-reported outcomes, which provide insights into how patients perceive the impact of the drug on their quality of life, symptoms, and overall well-being.
Real-World Data (RWD): Evidence from real-world studies, such as observational studies and post-marketing surveillance data, may also be required to evaluate the long-term effectiveness and safety of the drug in routine clinical practice.

So at least bring on the Real-World Data .
Kiwi

Ram. I agree that we are very unlikely to see another EPA trial the size and length of R-IT .
A trial of a high risk sub group ...say 2,000 PCI patients followed for 3 yrs for rate of re vascularization ? What's the patent life in the EU now with the new extension ?
If thats what it takes to get reimbursement in Germany and France it might be worth it . At least more / larger RWE studies.
Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company received a Decision to Grant from the European Patent Office (EPO) for a new patent covering VAZKEPA® (icosapent ethyl) that will extend VAZKEPA exclusivity eight additional years into 2039
Kiwi

alwayswatching

Congratulations another low for you !!!! What are you hoping for .50 cents ? IMO your thinking is just stupid !

Michael

Yeah, that was definitely one of the most birdbrainery things I've written now that I reflect on it. Haste makes waste!

The Amarin-Mochida Collaboration

1. Seen from Amarin’s viewpoint:

a. Amarin’s 10-K 2018 states:

“In June 2018, we entered into a collaboration with Mochida Pharmaceutical Co., Ltd., or Mochida, related to development and potential subsequent commercialization of drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA (eicosapentaenoic acid). The potential new product and indication opportunities contemplated under this agreement are currently in early stages of development.”

b. From 2019 till 2023 all Amarin’s 10-K have reported the following INVARIABLE text:

“In June 2018, we entered into a multi-faceted collaboration with Mochida Pharmaceutical Co., Ltd., or Mochida, related to the development and commercialization of drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. Among other terms in the agreement, we obtained an exclusive license to certain Mochida intellectual property to advance our interests in the United States and certain other territories. In addition, the parties will collaborate to research and develop new products and indications based on EPA for our commercialization in the United States and certain other territories. The potential new product and indication opportunities contemplated under this agreement are currently in early stages of development. Upon closing of the collaboration agreement, we made a non-refundable, non-creditable upfront payment of approximately $2.7 million. In addition, the agreement provides for milestone payments from us upon the achievement of certain product development milestones and royalties on net sales of future products arising from the collaboration, if any.”

c. Nota Bene: Amarin 10-K 2019 also confirmed at the end of the above statement: “In January 2020, we achieved certain milestones under the agreement, resulting in payment of $1.0 million to Mochida.’

2. Seen from Mochida’s viewpoint:

a. Mochida Annual Review 2018 stated:
“In June 2018, Mochida also entered an agreement with Amarin Corporation Plc Group to develop and
commercialize high-purity EPA products in the US and certain other countries under Mochida’s intellectual properties, including new EPA formulation.”

b. Mochida’s Annual Review 2019 affirmed:
“Mochida also entered into an agreement with Amarin Corporation Plc for the development and commercialization of EPA-based drug products in the United States and certain other territories by Amarin Corporation Plc.”
c. Nota Bene: Mochida’s 2019 wording replaced:
- “high-purity EPA products” by “EPA-based drug products” and,
- “under Mochida’s intellectual properties, including new EPA formulation” by “certain other territories by Amarin Corporation Plc.”

d. Mochida Annual review 2020 specified:

“Mochida also entered into an agreement with Amarin Corporation Plc for the development and commercialization of high-purity EPA formulations in the United States and certain other territories by Amarin Corporation Plc.”

It also listed Amarin as part of its “alliance partner” group.

e. Nota Bene: Mochida went back to using “high-purity EPA formulations” in lieu of “EPA-based drug products” but continued to ignore “under Mochida’s intellectual properties, including new EPA formulation.”

f. Strangely, the Mochida Integrated Report for 2021, 2022, and 2023 NO LONGER MENTIONS Amarin in any way.

3. In summary:

a. It is clear that Mochida had had second thoughts as early as 2019 regarding Amarin’s ability to fulfill its part of the 2018 Agreement “to develop and commercialize high-purity EPA products in the US and certain other countries under Mochida’s intellectual properties, including new EPA formulation.”

b. Mochida has been concerned by Amarin’s inability to promote Vascepa in the U.S. and avoid the erosion of its market share in the face of generics. Cutting off its nascent advertising spending, completely eliminating its sales force, and offering rebates to maintain 75% of the market at the expense of margins only corroborate this assessment. Moreover, declarations by Karim Mikhaïl and Per Wold Olsen that the U.S. market is lost could hardly have reassured the Japanese partner. To the contrary, these will back up future attempts by Mochida to have the 2018 Agreement declared legally void and nil.

c. What concerns Mochida most is the reference to the terms “intellectual property” which were erased in its Integrated reports for 2019 and 2020. Worse, Mochida no longer mentions a word about Amarin altogether since 2021. Gone are the short days when it was looked at as a collaborator and ally.

d. In this perspective, Mochida reasserted its attachment to and defense of its “intellectual property” rights by applying for U.S. patent protection for its MND-2119 (Epadel EM) product on July 17, 2020. The latter was granted on February 27, 2024.

e. Amarin, for its part, insists yearly on stating: “Among other terms in the agreement, we obtained an exclusive license to certain Mochida intellectual property to advance our interests in the United States and certain other territories.”

f. Questions impose themselves here:

- What is the state of relationship obtaining between Amarin and Mochida and where is it heading?

- Can the “exclusive license to certain Mochida intellectual property to advance our interests in the United States and certain other territories” be valid if Amarin is unable to put them to good use as well as promote its only product in terms of publicity/awareness (educating doctors, pharmacists, insurers and patients), and sales?

- To what extent is Amarin dependent on Mochida’s R&D capabilities? Does this reliance in a deteriorating relationship explain why Amarin scraped its Fixed Dose Combination program which KM and Executive Vice President, President R&D, Chief Scientific Officer Steve Ketchum had touted so much before?

- To what extent is LR-EtEPA’s development linked to Mochida’s R&D capabilities, and hence affected by this blurred and strained relationship?

- As Mochida obtained U.S. patent approval for Epadel EM who will eventually commercialize this product in the U.S. and “certain other territories”? And with what sales force?

- Mochida’s products being limited to the VHTG indication, can Vascepa’s 4mg compete against Epadel EM one-a-day in this market segment in the U.S., Europe, China and ROW?

- What do “certain other territories” cover?

- Is/are litigation(s) next to clarify the Mochida-Amarin collaboration?

g. For information:

- Mochida has 17,000+ employees.

- Mochida declared in its Integrated Report 2023: “We are also leveraging our alliances to globally expand our EPA drug with high purity in China, Thailand, Vietnam and the United States. In Thailand, the subsidiary of Meiji Seika Pharma Co., Ltd. obtained approval to import and market our EPA drug for the treatment of hypertriglyceridemia in October 2020 and commenced sales in April 2021. In Vietnam, an alliance partner of Meiji Seika Pharma is in the process of applying for approval to import and market our EPA drug.” It is worthwhile noting here Mochida does not identify who are its high-purity EPA drug marketing partners in the U.S. and China.

- Meiji Seika Pharma Co., Ltd (Japan) promotes and sells, inter alia, Mochida’s products overseas through a network of consolidated subsidiaries that cover India, most of the Far East (4 in China), Oceania (Australia & New Zealand), Europe and Africa. Production facilities are also found in India, Thailand and Spain.

- Amarin made the following payments to Mochida:

• “a non-refundable, non-creditable upfront payment of approximately $2.7 million” “upon closing the collaboration agreement” in June 2018.
• $1.0 million for “certain product development milestones achieved under the Agreement” in January 2020.
• $1.0 million for “exercising certain rights under the agreement” in December 2020.

- Amarin filed 9 U.S. provisional patent applications for LR-EtEPA during the period January 26 – June 2, 2022. It could not have done so if LR-EtEPA were the same product as MND-2119 for which Mochida had applied on July 17, 2020 – both priority claim and prior art would have impeded this.

- We do not know the status of these applications. After one year the United States Patent and Trade Mark Office (USPTO) must inform Amarin as quickly as possible if it is allowed, or not, to pursue the process. If allowed, Amarin must file a “final” so-called ‘regular” non-provisional application.

- Once the regular application is examined by a patent examiner, it is typical for the patent examiner to issue at least one Office Action. An examiner’s Office Action is a detailed report that outlines objections to the form of the application or the form or substance of the patent claims. It usually includes citations of prior art, often prior patents and published patent applications, that the examiner alleges to be relevant to the patentability of what’s claimed in the subject patent application.

- An Office Action is usually received by the applicant within 17 months of filing a regular patent application in the United States. The USPTO may request a new cycle of argumentations that would lead to a second final Office Action stating allowance or rejection of the patent application.

- Noteworthy, it took 43 months for Mochida to be granted USPTO protection for its MND-2119.

- As regards the rest of the world, Amarin used the PCT process on January 26, 2023 to ensure worldwide priority claim for LR-EtEPA based on the 9 non-provisional U.S. applications. This became effective with WIPO’s international publication of Amarin’s application on August 3, 2023.

- It is up to Amarin to move forward with applications for patent protection in certain individual countries and/or regional groupings as recognized by the PCT. Unfortunately, we lack total information regarding Amarin’s moves and intentions in this regard.

Vazkepa sales are disappointing in Europe so far. Why?
Which areas are the key reasons for the very slow start:
- Price??
- Awareness??
- Science and belief that it works??
- Better alternatives??
Anyone have a strong data based opinion ??
TIA

More Great News for Amarin! AMARIN has been voted as the number one stock for providing buying opportunities ! If you invested just $10,000 in AMRIN in 2007 today it would be worth, not quite $10,000 today. The desperate housewives of Investors HUb continue getting pumped and dumped . After being jilted by the loser Thero, who absconded with all of their money in their desperation they turned to the CAD AMRN. Yet every week hope springs eternal. Lets take a peak at the Fat Lady's pudding . Drum Roll Paaaaleeeze ta dum ta dum ta dum BOOM Its 96 pennies !! That's right its amazing, 96 pennies. Tune in next week where this the story line will be repeated as it has been for over 10 years. There is a secret coming out about AMRN that is going to make it boom. Buy more stock now while its cheap because buying opportunities like this don't occur often. Just almost every day for 17 years.

Rose - Ram, Whala made til argument OVER and OVER hundred of times since I joined here 2018.

That is why several posters over the years has suggested that he is somehow "related" to - S Nissen of Cleveland 👇️

Exactly Rosem....... I also remember one of the Adcom doctors commenting that he was worried that this would become cardio candy...... to me, that's a comment that smells like he was afraid too many prescriptions would be given out. I mean, that's the whole point. The evidence was too strong not too vote for and it was 16-0. He was probably Nissen's secret lover..... who knows!

Ram, you are definitely correct about that. I believe that Kiwi though has mentioned easier things like some RWE that insurers might already have from people being on V for a number of years now.

All those statin studies were not done by one company. The FDA vigorously defended R-I at the Adcom, and although It is my opinion that there is sufficient corroborating evidence for V (Jelis, Respect?, Evaporate, etc) what is the point of a p value if studies have to be redone a myriad of times.

311 shares moves it up $.08 in PM. Just insane this stock is!

Well Kiwi, let me help set your expectation properly.......you are not going to see another independent study like Reduce-It using V so that more cardiologists will become convinced. Not happening unless you can convince someone to do it. AMRN has no incentive to spend that kind of money again.

Well the quick answer is that those EU health depts that wasted tax euros reimbursing a drug with no CV benefit ( Omacor /Lovaza ) came under a lot of criticism .
So many now want independent confirming data
Kiwi

Ram Why do I have problem with the buyback . Short term its a win , long term a waste of $
So my plan is to accumulate under $1 ...if the buyback pushes the PPS over $1.50 ...I"ll sell ( 50% return ) unless I see them making concrete plans to increase the level of evidence that Germany and France will likely want before reimbursing.
Why risk a trial ( even a small one in a select subgroup ) and risk a different result ...because without that independent trial many in the Cardiology community remain unconvinced.
There were at least 13 independent trials confirming risk reduction of Statins
At least 3 for PCSK9's ...
Germany has always wanted independent placebo controlled trials before reimbursing CV drugs ...at least in recent years . If you aware of a CV drug reimbursed in Germany based on 1 double blinded trial , please post it
Kiwi

Your are making my point that if they were enamored with Gissi-Prevenzione, then they should over the top with R-I. Gissi was an open labelled study with no measurement of Omega-3 of participants. Many other facets too. No comparison to R-I.

So Kiwi, since you acknowledged a share buyback will most likely cause the PPS to rise, why do you have a problem with that? All longs in this stock are in the stock for the PPS to rise. You discount the fact that this management team may actually know what they are doing. AND, Your fantasy of AMRN doing another placebo controlled double blind study is never coming to fruition. Why would they do do that and risk a different result when they already received the desired indication?

RMB. I think it was this trial. The results of the GISSI-Prevenzione trial in the general framework of secondary prevention that started the whole love affaire with Lovaza / Omacor .
Results weren't independently confirmed in at least Dr Nissens trial with EPA/DHA and probably others beforehand.

Trick is indépendant confirmation of results ...preferably by another double blinded placebo controlled trial of at least a sub group of the initial trial .
Kiwi

Interesting that those EU countries reimbursed handsomely for Lovaza/Omacor, then stopped doing so and now with Vazkepa although not as effective at lowering trigs, nonetheless lowers trigs, doesn’t raise LDL, and have proof of reducing CVD (something Lovaza never has shown), they are so residtant to reimbursing. You would think they would be falling over themselves to cover V.

Tat, The appellate court can only make a determination about the the ruling from the district court. Was that ruling correct based on the relevant law? The practices of insurance companies don't meet the legal definition of direct infringement. It is inducement.
Sleven,

So here's an example of what these AMRN guys / girls are getting

Explanation of Responses:
1. On April 18, 2024, following the conclusion of the Issuer's annual general meeting of shareholders for 2024, the Reporting Person was granted an option to purchase 179,795 Ordinary Shares under the Plan and the Policy. The shares subject to this option shall vest and become exercisable over three years, with 33% to vest on the first anniversary of the grant date and the remaining balance vesting in equal quarterly installments over the subsequent two years on the first day of each April, July, October and January.

So hey ...how can we get the PPS up so we can cash out next April .
Well for starters ...lets do a share buyback

Kiwi

$AMRN Two easy steps in the ESC 2021 Guidelines for significantly reducing residual CVD risk in all European regions includes icosapent ethyl (VAZKEPA®). Come on France, Germany, and Italy, get with the program!

https://academic.oup.com/eurjpc/article/31/6/754/7602450?login=false&utm_source=etoc&utm_campaign=eurjpc&utm_medium=email

RE your view
Do you think Reduce It would even exist today if FDA had not mandated it? What would Amarin have to sell if they didnt?
You don't know that AMRN would never have run a CV outcome trial .

They may have on their own , for select subgroups like revascularisation rates following a PCI
What would they have been selling ....an alternative to Lovaza ...which labelled as Omacor had been selling pretty well in the EU

Kiwi

Re Everyone makes money off Amarin except the shares holders. Well no . Some shareholders in the past made significant $ . Some here may remember Biochia ...sold everything early 2020 . JL did pretty well also ..selling down before the Judge Du decision .
Anyone buying under $1 now has a reasonable chance of making some $ .
Why ?
Well as you pointed out ....the biggest beneficiaries of the share buyback are all the AMRN insiders who were recently granted a ton of options and RSU's .
Buying back stock should raise the PPS allowing them to cash out some of these options when they vest ...we of course will get the crumbs ...well at least those of us buying under $1 .
Not investment advice
Risk only what U can afford to lose
JMO
Kiwi

Nope. High TG's with high LDL was a known risk factor . Lovaza was the go to, to lower high TG's . Problem was it raised LDL levels significantly for some.
HeFH patients such as myself often also have mixed D ( High TG with low HDL ) . I couldn't take Lovaza because my LDL was still around 180mg/dl in max dose Lipitor .
My TG's in the low 200's .
So ...back in the day of the Anchor SPA ...we were waiting for AMR 101 ( now Vascepa ) to be approved for reducing high TG's without raising LDL cholesterol .
I think it was a Co called Reliant that developed Lovaza and sold it to GSK ....this is before we found Lovaza did not reduce CV events .
So if the Anchor indication had been approved ...AMRN would have existed as an alternative for those that couldn't take Lovaza.
Omacor ( Lovaza in the EU ) was big business in many EU countries , especially Spain that reimbursed generously for it .

Kiwi

This is true. If not for the FDA forcing REDUCE-It, Amarin probably doesn’t exist today. And they likely would have sold the company in a fire sale.

ramfan

They already made a deal with a broker I believe it was the last conference they presented at. Since its only 50 million dollars the broker has probably already purchased all the shares in advance IMO Everyone makes money off Amarin except the shares holders

Michael

thanks to the FDA requiring the Reduce It trial before it could get going and Judge Du's ruling

Think about what you just wrote carefully... the only reason you're even here now complaining about how Amarin is being treated over the Reduce It CVD label is because the FDA forced Amarin to run it.

Do you think Reduce It would even exist today if FDA had not mandated it? What would Amarin have to sell if they didnt?

Everything you say rings true. I always thought the action against Health Net was merely to force the insurance company into a settlement so that it would conform, at a minimum, to the practices of the other insurance companies. I don't believe Amarin ever intended to seek damages and certainly didn't want to set some sort of precedent that would affect, and offend, all insurance companies, many of whom Amarin was trying to negotiate with at the time. If I recall right, Health Net's violations were pretty blatant. So Amarin likely got what it sought, a level playing field with generics from that company.

As for the generic bias, you make valid and accurate points. I guess the Amarin case differs from so many other companies, as you know, because its price isn't all that much different from generics and it never got a chance to make money with Vascepa before generics entered the picture, thanks to the FDA requiring the Reduce It trial before it could get going and Judge Du's ruling.

BBI, you know more than you think..........they will carefully execute the buying and we won't know until the shares are actually purchased. I suspect that we won't even know the request was approved until after AMRN acquired some of the shares....it also wouldn't surprise me if an arrangement is already in place with a broker that has been accumulating shares for AMRN in anticipation of them getting this approval.

You should try viewing it thru the lens of how politically popular generic drugs are in the US. There's a reason 85%+ of all Rx in this country are generic. It's by legislative design. This board views it as "poor Amarin vs. vulture generics" cause you're invested in Amarin and your pocket book has personally suffered. The rest of the country views it as "greedy brand drug maker vs. generics that help poor grandma afford for her medicine". Has been all along and the facts dont matter. The appellate court commenting on some nothing disclaimer generics could use like "Not for XYZ indication" on a label should tell you they're gonna give the generics an easy CYA out on this and not cross the skinny label provisions in HW because too many people view it as the only way to ensure cheaper drugs. Besides, the real infringement occurs at the insurance level with preferred tier coverage and mandated substitution and Amarin doesnt have the clout to bite that hand that feeds them. They tried, they settled, and nothing changed.

I agree...judges, especially younger ones, like many human beings, have their eye on the next potential step in their careers...They don't want to make a misstep, that might mitigate against them in the future....This includes possible advancement to a higher position within the court or even to a higher court.

Even on the Supreme Court, it is not unheard of, to have a justice entertain still higher ambitions.

I know nothing about how much buying of a stock it takes to move the price, but I would imagine you'd have to really space out your purchases if you're planning to drop $50 million into a stock. Wouldn't the sudden purchase of so many shares make the share price explode to $6 or higher? I would think you'd have too limit your buys to 200,000 to 300,000 shares a day, tops, to keep the share price down while you carry out purchases. But I've also seen companies announce share buyback plans and never come close to buying as many shares as they pre-announced.